^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
alveltamig (ZG006)
i
Other names: ZG006
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
AbbVie, Suzhou Zelgen
Drug class:
CD3 agonist, DLL3 inhibitor
Related drugs:
3d
Study of ZGGS34 in Participants With Advanced Solid Tumors (clinicaltrials.gov)
P1/2, N=400, Recruiting, Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Not yet recruiting --> Recruiting
Enrollment open
|
HER-2 (Human epidermal growth factor receptor 2) • MSI (Microsatellite instability) • MUC17 (Mucin 17)
|
MSI-H/dMMR
|
alveltamig (ZG006)
3d
Study of ZG006 in Combination With PD-1/PD-L1 Immune Checkpoint Inhibitors as First-Line Standard Therapy in Participants With Extensive Stage Small-Cell Lung Cancer (clinicaltrials.gov)
P1, N=100, Recruiting, Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Not yet recruiting --> Recruiting | Trial completion date: Dec 2027 --> Dec 2028 | Trial primary completion date: Dec 2027 --> Dec 2028
Enrollment open • Trial completion date • Trial primary completion date • Checkpoint inhibition
|
Hetronifly (serplulimab) • alveltamig (ZG006)
4ms
Study Comparing ZG006 With Investigator-Selected Chemotherapy in Participants With Relapsed Small Cell Lung Cancer (clinicaltrials.gov)
P3, N=420, Recruiting, Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Not yet recruiting --> Recruiting
Enrollment open
|
topotecan • alveltamig (ZG006)
4ms
ZG006 and ZG005 in Participants With Small Cell Lung Cancer or Neuroendocrine Carcinoma (clinicaltrials.gov)
P1/2, N=350, Recruiting, Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Not yet recruiting --> Recruiting
Enrollment open
|
alveltamig (ZG006) • nilvanstomig (ZG005)
4ms
Study of ZG006 in Participants With Small Cell Lung Cancer or Neuroendocrine Carcinoma (clinicaltrials.gov)
P1/2, N=54, Recruiting, Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Trial completion date: Oct 2025 --> Oct 2026 | Trial primary completion date: Sep 2025 --> Sep 2026
Trial completion date • Trial primary completion date
|
DLL3 (Delta Like Canonical Notch Ligand 3)
|
alveltamig (ZG006)
5ms
Study of ZGGS34 in Participants With Advanced Solid Tumors (clinicaltrials.gov)
P1/2, N=400, Not yet recruiting, Suzhou Zelgen Biopharmaceuticals Co.,Ltd
New P1/2 trial
|
alveltamig (ZG006)
5ms
Study of ZG006 in Combination With PD-1/PD-L1 Immune Checkpoint Inhibitors as First-Line Standard Therapy in Participants With Extensive Stage Small-Cell Lung Cancer (clinicaltrials.gov)
P1, N=100, Not yet recruiting, Suzhou Zelgen Biopharmaceuticals Co.,Ltd
New P1 trial • Checkpoint inhibition
|
Hetronifly (serplulimab) • alveltamig (ZG006)
5ms
ZG006-002: Dose Escalation Study of ZG006 in Participants With Advanced Small Cell Lung Cancer or Neuroendocrine Carcinoma, Followed by Dose Expansion Study in Participants With Advanced Small Cell Lung Cancer (clinicaltrials.gov)
P1/2, N=265, Recruiting, Suzhou Zelgen Biopharmaceuticals Co.,Ltd | N=105 --> 265
Enrollment change
|
alveltamig (ZG006)
7ms
Study Comparing ZG006 With Investigator-Selected Chemotherapy in Participants With Relapsed Small Cell Lung Cancer (clinicaltrials.gov)
P3, N=420, Not yet recruiting, Suzhou Zelgen Biopharmaceuticals Co.,Ltd
New P3 trial
|
topotecan • alveltamig (ZG006)
10ms
ZG006 and ZG005 in Participants With Small Cell Lung Cancer or Neuroendocrine Carcinoma (clinicaltrials.gov)
P1/2, N=350, Not yet recruiting, Suzhou Zelgen Biopharmaceuticals Co.,Ltd
New P1/2 trial
|
alveltamig (ZG006) • nilvanstomig (ZG005)
11ms
Study of ZG006 in Participants With Neuroendocrine Prostate Cancer (clinicaltrials.gov)
P2, N=60, Not yet recruiting, Suzhou Zelgen Biopharmaceuticals Co.,Ltd
New P2 trial
|
alveltamig (ZG006)
1year
A Phase 1 Dose Escalation Study of ZG006 in Patients With Small Cell Lung Cancer (clinicaltrials.gov)
P1, N=30, Recruiting, Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Not yet recruiting --> Recruiting | Initiation date: Dec 2024 --> Mar 2025
Enrollment open • Trial initiation date
|
alveltamig (ZG006)
Share via
